Drug: emend Quarter: 2016Q3
Total Records: 233 Number of Pages: 12
| DRUGNAME | PT | EventCount |
|---|---|---|
| EMEND (FOSAPREPITANT DIMEGLUMINE) | Malignant neoplasm progression | 2 |
| EMEND (FOSAPREPITANT DIMEGLUMINE) | No adverse event | 2 |
| EMEND (FOSAPREPITANT DIMEGLUMINE) | Product use issue | 2 |
| EMEND | Abdominal pain | 1 |
| EMEND | Adverse reaction | 1 |
| EMEND | Amnesia | 1 |
| EMEND | Asthenopia | 1 |
| EMEND | Balance disorder | 1 |
| EMEND | Blood creatinine increased | 1 |
| EMEND | Blood lactic acid increased | 1 |
| EMEND | Blood pressure abnormal | 1 |
| EMEND | Blood pressure decreased | 1 |
| EMEND | Blood urine present | 1 |
| EMEND | Body temperature fluctuation | 1 |
| EMEND | Cardiac arrest | 1 |
| EMEND | Cardio-respiratory arrest | 1 |
| EMEND | Cerebrovascular accident | 1 |
| EMEND | Colon cancer | 1 |
| EMEND | Coma | 1 |
| EMEND | Dehydration | 1 |
Total Records: 233 Number of Pages: 12